

=> b reg
FILE 'REGISTRY' ENTERED AT 11:33:24 ON 29 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 APR 2008 HIGHEST RN 1017984-01-8
DICTIONARY FILE UPDATES: 28 APR 2008 HIGHEST RN 1017984-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> b hcap
FILE 'HCAPLUS' ENTERED AT 11:33:48 ON 29 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Apr 2008 VOL 148 ISS 18
FILE LAST UPDATED: 28 Apr 2008 (20080428/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitrn l18 tot

```
L18 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN
AN      2006:818216 HCAPLUS
IN      145:241693
II      Pyridazine-based SCD-1 inhibitors for use in combination therapy to treat
        adverse weight gain associated with a drug therapy
IN      Purpose, Kashinath; Abreu, Melyny; Konstantinos, Mikhail; Harvey,
        Daniel; Hudson, Cindy; Li, Wenbo; Tu, Chi; Sun, Sengen; Holladay, Mark;
        Heintzinger, Heinrich; Rajendran, Rajesh; Muehle, Michael; Trautwein,
        Cécile; Mikhail, Fu; Wang, Xian; Hou, Duanqin; Liu, Gifeng; Maine, Vandana;
        Seitz Bagherzadeh, Mehran
PA      Xenon Pharmaceuticals Inc., Can
SO      PCT Int. Appl., 143pp.
EN      CODEN: PIKXDD
LA      Patent
LT      LA English
```

PAT. NO.	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO-2006086445	A2	20060817	2006W0-UG004383	20060208
	WO-2006086445	A3	20060914		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, GN, GR, GT, HK, HU, IL, IN, IS, IE, JP, KE, KG, KH, KR, KZ, LA, LB, LC, LR, LU, LV, LY, MA, MC, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SV, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, ME, NL, PL, PT, RO, SE, SI, SK, TR, BF, BG, BR, CA, CC, CG, CI, CL, CN, CO, CR, CU, DE, DK, DM, EC, EE, EG, ES, FI, FR, GB, GE, GH, GM, KE, LS, MM, MG, NA, SD, SE, TJ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, NL, RU, TJ, TM					
	WO-2006121761	A1	20060817	2006AU-000212761	20060208
CA-2597067	A1	20060817	2006CA-00257067		20060208
EP-1846035	A2	20071024	2006EP-00734555		20060208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, ME, NL, PL, PT, RO, SE, SI, SK, TR					
MX-200709592	A	20071016	2007MX-00009592		20070808
IN-200703940	A	20071123	2007IN-0003940		20070910
US-0635040	P	20040104	2006US-08009724		20070925
PRAT	20050051584P	P	20050209		
	2006W0-UG004383	W	20060208		
OS	MARKPAT 145:241683				




AB This invention is directed to the use of SCD-1 inhibitors of the formula I
[m, n = independently 1-3; W = a direct bond, NHCO and derivs., O, OCONH
and derivs., CO, NHC(=O)NH and derivs., etc.; V = CO, CS, CONH and
derivs., etc.; G, J, L, M = independently N, CH and derivs., provided that
at most 2 of G, J, L, and M are N; R₂, R₃ = independently alk(en)yl, aryl,

118 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STIN (Continued)
etc.; each R5, R5a, R6, R6a, R7, R7a, R8, R8a = independently H, alkyl; or
R5R5a (e.g., II) in combination with other drug therapies, particularly
drug therapies for diabetes, to treat the adverse wt. gain (no data). 30
Reaction schemes along with the assocd. general preps., and 388 claimed
comps. are given.

[illegible]

118 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(SCD-1 inhibitor; use of pyridazine stearoyl-CoA desaturase-1
inhibitors in combination with other drug therapies for treating
adverse wt. gain)
RN 842170-92-7 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-[5-[4-[2-(trifluoromethyl)benzoyl]-1-
piperazinyl]-2-pyridinyl]- (CA INDEX NAME)




118 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:120713 HCAPLUS
DN 142:219309
TI Preparation of piperazinylpyridines as inhibitors of human stearyl CoA
desaturase (hSCD).
IN Abreo, Melwyn; Harvey, Daniel F.; Kondratenko, Mikhail A.; Li, Wenba
Kamboj, Rajender; Kodumuru, Vishnumurthy; Winther, Michael D.; Gschwend,
Heinz W.; Chakka, Nagasree; Liu, Shifeng; Sviridov, Serguei; Sun, Shaoyi
PA Xenon Pharmaceuticals Inc., Can.

[illegible][illegible]

L18 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 ester (prepn. given) and piperazin-1-yl-(2-(trifluoromethyl)phenyl)methanone
 (prepn. given) in PhMe were added to a mixt. of Cs2CO3, Pd(OAc)2, and
 BINAP followed by heating at 100° for 26 h to give 13a
 5-[4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl]pyridine-2-carboxylic acid
 (3-phenylpropyl)amide.
 IT 842170-92-7P 842170-93-8P 842170-94-9P
 842170-95-0P 842170-96-1P 842170-97-2P
 842170-98-3P 842170-99-4P 842171-03-3P
 842171-04-4P 842171-05-5P 842171-06-6P
 842171-07-7P 842171-08-8P 842171-09-9P
 842171-10-2P 842171-12-4P 842171-15-7P
 842171-17-9P 842171-19-1P 842171-21-5P
 842171-23-7P 842171-25-9P 842171-27-1P
 842171-29-3P 842171-31-7P 842171-35-1P
 842171-37-3P 842171-39-5P 842171-41-9P
 842171-93-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of piperazinyipyridines as inhibitors of human
 stearoyl CoA desaturase)
 IT 842171-55-9P 842171-57-7P 842171-59-9P
 842171-61-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of piperazinyipyridines as inhibitors of human stearoyl CoA
 desaturase)
 IT 842170-92-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of piperazinyipyridines as inhibitors of human
 stearoyl CoA desaturase)
 RN 842170-92-7 HCAPLUS
 CN Benzenepropanamide, 4-fluoro-N-[5-[4-[2-(trifluoromethyl)benzoyl]-1-
 piperazinyl]-2-pyridinyl]- (CA INDEX NAME)



=> d bib abs hitstr l2l tot

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
AN 2005:474938 HCAPLUS
DN 143:7740

II Preparation of nicotinic acid derivatives and their use as therapeutic agents for treating stearyl-CoA desaturase-related diseases
Fu, Jian-Min; Kodumuru, Vishnumurthy; Sun, Shaoyi; Wintner, Michael D.; Fine, Richard M.; Harvey, Daniel F.; Klebanov, Boris; Gray-Keller, Mark P.; Gschwend, Heinz W.; Li, Wenbo
CA
US 5. Pat. Appl. Publ., 59 pp., Cont.-In-part of U.S. 326,210.
CODEN: USXXCO
D7 Patent
LA English
FAM_CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20050119251	A1	20050602	2004US-000885901	20040706 <--
PRAI 2001US-00343516P	P	20011221	<--	
2002US-00345060P	P	20020709	<--	
2002US-000326210	A2	20021220	<--	
OS MARPAT 143:7740				



AB Methods of treating stearyl-CoA desaturase-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula I, e.g., 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)nicotinamide. Pharmaceutical compns. comprising the compds. of formula I are claimed as are the compds. themselves. A method of preparing the compds. is exemplified. The disease or condition is a disease or condition related to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol or the process of reverse cholesterol transport. The disease or condition is selected from the group consisting of Type II diabetes, impaired glucose tolerance, insulin resistance, hypertension, obesity, hypertriglyceridemia, low HDL, lipidemia, dyslipidemia, microalbuminemia, hyperuricemia, hypercoagulability, hyperleptinemia, metabolic syndrome and any combination of these.

IT 852548-31-3P, N-(2-Cyclopropylethyl)-2-methoxy-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-N-pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USSES (Uses)
(drug candidate) preparation of nicotinic acid derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases

RN 852548-31-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-2-methoxy-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



IT 361209-76-9P, N-[3-(imidazol-1-yl)propyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361209-79-2P,

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 361209-80-5P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 361209-81-6P, 6-[4-(2,3,4,5-Tetrachlorobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 361209-88-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 361210-17-5P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 361450-94-4P, N-(2-(3-Chlorophenyl)ethyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361451-03-6P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[2-(3-chlorophenyl)ethyl]nicotinamide 361451-43-6P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-[2-(3-chlorophenyl)ethyl]nicotinamide 361452-29-1P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361452-33-7P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 361452-34-6P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 361452-43-9P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 361452-60-0P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 361452-63-3P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 361453-93-2P, N-(1-Methyl-3-phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]-N-pyridine 361454-25-3P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide 361464-05-3P, N-Pentyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361464-25-7P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361464-27-9P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361464-30-4P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361464-42-8P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361465-01-2P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361465-07-6P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-pentylnicotinamide 361466-83-9P, N-(3-Butoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361466-93-5P, N-(3-Butoxypropyl)-6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]nicotinamide 361466-96-8P, N-(3-Butoxypropyl)-6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]nicotinamide 361466-99-1P, N-(3-Butoxypropyl)-6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]nicotinamide 361467-19-8P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-butoxypropyl)nicotinamide 361467-87-0P, N-(3-Butoxypropyl)-6-[4-(2,4-dimethylbenzoyl)piperazin-1-yl]nicotinamide 361467-99-4P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-butoxypropyl)nicotinamide 361526-44-5P, N-(3-Phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361526-48-9P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 361526-54-7P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 361526-74-1P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 361538-99-0P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide 361540-17-2P, 6-[4-(2,3,5-Dichlorobenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 361980-14-5P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 361989-24-4P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 361991-32-4P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 503281-65-0P, N-Butyl-6-[4-(2,4-dichlorobenzoyl)piperazin-1-yl]nicotinamide 503281-66-1P, N-Butyl-6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]nicotinamide 503281-67-2P, N-Butyl-6-[4-(3,5-dichlorobenzoyl)piperazin-1-yl]nicotinamide 503281-81-0P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-butylnicotinamide 503282-19-7P, N-Butyl-6-[4-(2,4-dimethylbenzoyl)piperazin-1-yl]nicotinamide 503317-33-7P, N-(3-Methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503317-36-2P, 6-[4-(2,4-

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide 503317-39-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide 503317-40-6P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide 503317-47-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide 503318-41-4P, N-(3-Dimethylaminopropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503318-65-6P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide 503318-66-9P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide 503318-74-9P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide 503318-94-3P, N-(3-Dimethylaminopropyl)-6-[4-(2,4-dimethylbenzoyl)piperazin-1-yl]nicotinamide 503324-63-6P, 6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 503324-68-3P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 503324-76-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 503324-96-7P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 503324-98-9P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 503325-91-5P, N-(3-Ethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503325-96-0P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide 503325-97-1P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide 503326-04-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide 503326-24-7P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide 503326-27-0P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide 503326-46-3P, N-(4-Phenylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503327-17-1P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 503421-63-4P, N-(1,3-Dimethylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503421-73-6P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503421-75-6P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503421-77-0P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503421-94-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503422-32-0P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503422-36-4P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide 503453-15-4P, N-Phenethyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503453-18-7P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 503453-26-7P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 503453-44-9P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 503453-47-2P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 504417-35-0P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide 504417-38-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide 504417-46-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 504418-10-4P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-phenethylnicotinamide 504425-73-4P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide 504426-87-3P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide 504428-07-3P, N-Butyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 504429-46-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-imidazol-4-yl)ethyl]nicotinamide 852548-17-5P, N-(2-Cyclopropylethyl)-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-21-1P, N-(2-Cyclopropylethyl)-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-22-2P, N-(3-Cyclopropylpropyl)-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-24-4P, 6-[4-(5-fluoro-2-


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

trifluoromethylbenzoyl)piperazin-1-yl]-N-(4-methylpentyl)nicotinamide 852548-36-6P, N-(2-Ethoxypropyl)-6-[4-(5-fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-38-8P, N-(2-Cyclopropylethyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-39-1P, 2-Oxo-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-2,2-dihydropyridine-3-carboxylic Acid (2-cyclopropylethyl)amide 852548-47-5P, 6-[4-(2-Phenylcyclopropylcarbonyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852548-58-4P, N-Butyl-6-[4-(2-mercaptobenzoyl)piperazin-1-yl]nicotinamide 852548-65-3P, N-(3-Methylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-67-5P, N-(3-Methylbutyl)-6-[4-(2-dichlorobenzoyl)piperazin-1-yl]nicotinamide 852548-69-7P, N-(3-Methylbutyl)-4-(2-trifluoromethyl-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-71-1P, 2-Chloro-5-fluorbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-73-3P, 2-Chloro-3-(3-methylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-81-3P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2,4-dichlorobenzoyl)piperazin-1-yl]nicotinamide 852548-83-5P, 6-[2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852548-85-7P, N-(3-Methylbutyl)-6-[2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-91-5P, N-Pentyl-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852548-92-6P, N-(3-Methylbutyl)-6-[4-(Naphthalen-1-ylcarbonyl)piperazin-1-yl]nicotinamide 852548-94-8P, N-(2-(3-Chlorophenyl)ethyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852549-03-2P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)nicotinamide 852549-05-4P, N-(3-Phenylpropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852549-11-2P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide 852549-15-6P, N-(1,3-Dimethylbutyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852549-17-8P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852549-77-0P, N-Pentyl-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852549-89-4P, N-(3-Ethoxypropyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852549-91-8P, N-(2-Ethylsulfonyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852549-93-0P, N-(1,3-Dimethylbutyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852549-95-2P, N-(3-Methylbutyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852549-99-6P, N-(3-Butoxypropyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-01-7P, N-(3-Dimethylaminopropyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-03-9P, N-(3-Isopropoxypropyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-05-1P, N-(1-Methylbutyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-07-3P, N-Butyl-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-09-5P, N-Hexyl-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-11-9P, N-(2-Methylbutyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-14-2P, N-(4-Phenylbutyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-17-5P, N-(1-Methyl-3-phenylpropyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-19-7P, N-Phenethyl-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-21-1P, 6-[4-(2-Phenylcyclopropylcarbonyl)piperazin-1-yl]-N-(tetrahydrofuran-2-yl)methylnicotinamide 852550-23-3P, N-[2-(3H-imidazol-4-yl)ethyl]-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-25-5P, N-(2-Imidazol-1-yl)propyl)-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide 852550-38-0P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide 852550-41-3P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)nicotinamide 852550-42-6P, N-(3-Ethoxypropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-43-7P, N-(2-Ethoxypropyl)-6-[4-(3,5-dichlorobenzoyl)piperazin-1-yl]nicotinamide 852550-44-6P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-isopropoxypropyl)nicotinamide 852550-45-9P, N-(3-Methylbutyl)-6-[4-(3-

[illegible]

L21 ANSWER 1 OF 5 NCAPLUS COPYRIGHT 2008 ACS ON STIN (Continued)
N-Hexyl-6-[4-(naphthalen-2-yl)caronyl]piperazin-1-yl]nicotinamide
825551-50-9P, N-[3-(Dimethylaminopropyl)-6-[4-(naphthalen-1-
yl)caronyl]piperazin-1-yl]nicotinamide 825455-51-0P,
N-[3-(Dimethylaminopropyl)-6-[4-(naphthalen-2-yl)caronyl]piperazin-1-
yl]nicotinamide 825551-52-1P, N-[3-(Dimethylaminopropyl)-6-[4-(
naphthalen-2-yl)caronyl]piperazin-1-yl]nicotinamide
NOTE: PA# (Pharmacological activity); SYN (Synthesis preparation); THU
(Therapeutic use); BIO (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; prepn. of nicotinamide coxs, and their use as
therapeutic agents for treating stearyl-CoA desaturase-mediated
diseases)


RN 361209-95 NCAPLUS
CN 3-Pyridinedicarboxamide, N-[3-(3H-indolizino[1,2-b]pyrrolyl)-6-[4,(2,3,4,5-




```

RN      361209-79-2  HCAPLUS
CN      3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1H-
        imidazol-1-yl)propyl]- (CA INDEX NAME)


```



RN 361209-80-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361209-81-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361209-88-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)

21 ANSWER 1 OF 5 ICAPULUS COPYRIGHT 2008 ACS ON STN (Continued)


yl]nicotinamide 825550-94-6P, 6-[4-(2,4-Dinitrofluorobenzyl)pipera-
zine-1-yl]-N-hexyl-1-nicotinamide 825550-95-9P
N-(3-Methoxyphenyl)pipera-1-yl]-N-(2-fluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825550-96-0P, 6-[4-(2,5-Dichlorofluorobenzyl)pipera-1-yl]-N-(2-methylbutyl)nicotina-
mide 825550-97-1P, N-Hexyl-6-[4-(4-trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825550-98-0P, N-(3-Methoxyphenyl)pipera-1-yl]nicotinamide 825550-99-3P, N-(2-Methylbutyl)-6-[4-(4-trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-00-0P, N-(3-Methoxyphenyl)pipera-1-yl]nicotinamide 825551-01-0P, 6-[4-(2,4-Dinitrofluorobenzyl)pipera-1-yl]-N-(2-
-methylbutyl)nicotina-
N-(2-Methylbutyl)-6-[4-(2,4-trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-03-2P, 6-[4-(2-Bromobenzyloxy)pipera-1-yl]-N-(2-ethyl-3-phenylthioethyl)nicotina-
mide 825551-04-2P, 6-[4-(2-Bromo-5-methoxybenzyloxy)pipera-1-yl]-N-(3-isopropoxypropyl)nicotina-
mide 825551-05-4P, N-(3-Methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzyl)pipera-1-yl]nicotina-
mide 825551-06-3P, N-(3-Methoxyphenyl)pipera-1-yl]nicotinamide 825551-07-6P, N-(3-Isopropoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzyl)pipera-1-yl]nicotina-
mide 825551-08-0P, N-(3-Methoxyphenyl)pipera-1-yl]nicotinamide 825551-09-8P, N-Hexyl-6-[4-(2,3,4,5-tetrafluorobenzyl)pipera-1-yl]nicotina-
mide 825551-10-1P, N-(2-Ethyl-3-phenylthioethyl)-6-[4-(2,3,4,5-tetrafluorobenzyl)pipera-1-yl]nicotina-
mide 825551-11-2P, N-(3-Dimethylaminopropyl)-6-[4-(4-Trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-12-3P, N-(3-Ethoxypropyl)-6-[4-(3,4-Dichlorofluorobenzyl)pipera-1-yl]nicotina-
mide 825551-13-4P, 6-[4-(3,5-Dichlorobenzyl)pipera-1-yl]-N-(2-methylbutyl)nicotina-
mide 825551-14-2P, N-(3-Methylbutyl)-6-[4-(4-Trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-15-6P, N-Butyl-6-[4-(4-trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-16-7P, N-(3-Isopropoxypropyl)-6-[4-(4-trifluoromethylbenzyl)pipera-1-yl]nicotina-
mide 825551-17-0P, N-(3-Methoxyphenyl)pipera-1-yl]nicotina-
mide 825551-18-1P, N-Butyl-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-19-2P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-20-4P, N-Butyl-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-21-6P, 6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-22-8P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-23-6P, N-(3-Methoxyphenyl)pipera-1-yl]nicotina-
mide 825551-24-7P, N-Butyl-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-25-8P, 6-[4-(Naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-26-9P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-27-1P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-28-3P, N-Hexyl-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-29-4P, N-(3,5-Dimethylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-30-6P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-31-8P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-32-0P, N-(2-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-33-2P, N-(2-Ethyl-3-phenylthioethyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-34-4P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-35-6P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-36-8P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-37-0P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-38-2P, N-(2-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-39-4P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-40-6P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-41-8P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-42-0P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-43-2P, N-Butyl-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-44-4P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-45-6P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-46-8P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-47-0P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-48-2P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-49-4P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-50-6P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-51-8P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-52-0P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-53-2P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-54-4P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-55-6P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-56-8P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-57-0P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-58-2P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-59-4P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-60-6P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-61-8P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-62-0P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-63-2P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-64-4P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-65-6P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-66-8P, N-(3-Isopropoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-67-0P, N-(3-Ethoxypropyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-68-2P, N-(3-Methylbutyl)-6-[4-(naphthalen-1-yl)carboxyl]pipera-1-yl]nicotina-
mide 825551-




RN 361210-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 361450-94-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361451-03-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[2-(3-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 361451-43-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(3-chlorophenyl)ethyl]- (CA INDEX NAME)




RN 361452-29-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-4-yl)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361452-33-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-34-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 361452-43-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-60-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 361452-63-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361464-30-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361464-42-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)



RN 361465-01-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361465-07-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361466-83-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361453-93-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361454-25-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)



RN 361464-05-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361464-25-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 361464-27-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361466-93-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361466-96-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361466-99-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 361467-19-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-butoxypropyl)- (CA INDEX NAME)




RN 361467-87-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361467-99-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-butoxypropyl)- (CA INDEX NAME)




RN 361526-44-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 361526-48-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361526-49-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361526-54-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361991-32-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 503281-65-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503281-66-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503281-67-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503281-81-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-butyl- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 361526-74-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361538-99-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)



RN 361540-17-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 361980-14-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 361989-24-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503282-19-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503317-33-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503317-38-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503317-39-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503317-40-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503317-47-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 503318-61-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503318-65-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 503318-66-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 503318-74-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503324-98-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503325-91-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503325-96-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503325-97-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503326-04-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503318-94-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503324-63-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 503324-68-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503324-76-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 503324-96-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503326-24-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-ethoxypropyl)- (CA INDEX NAME)




RN 503326-27-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 503326-86-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503327-14-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 503327-17-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503421-63-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503421-73-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)



RN 503421-75-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503421-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503421-94-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503453-44-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 503453-47-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)



RN 504417-35-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 504417-38-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 504417-46-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 503422-32-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)




RN 503422-36-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(1,3-dimethylbutyl)- (CA INDEX NAME)



RN 503453-15-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 503453-18-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 503453-26-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 504418-10-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 504425-73-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)



RN 504426-87-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 504428-07-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 504429-46-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 852548-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852548-21-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclobutylethyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-22-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-cyclopropylpropyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-24-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]-N-(4-methylpentyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



RN 852548-65-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-67-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 852548-69-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-4-(trifluoromethyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-71-1 HCAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-5-fluoro-N-(3-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-73-3 HCAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(3-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 852548-26-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3,3-dimethylbutyl)-6-[4-[5-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-28-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852548-39-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-1,2-dihydro-2-oxo-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-47-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 852548-58-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-[2-(mercaptobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 852548-81-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852548-83-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-oxo-4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)



RN 852548-85-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[2-oxo-4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-91-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852548-92-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852548-94-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852549-03-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852549-05-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-11-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852549-15-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-17-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 852549-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-[(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852549-89-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-91-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)




RN 852549-93-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-95-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852549-97-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852549-99-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-01-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)


RN 852550-03-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-05-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-07-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852550-09-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-11-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-14-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-17-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-19-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 852550-21-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 852550-23-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-25-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(2-phenylcyclopropyl)carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-38-0 HCAPLUS


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-46-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-47-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852550-48-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-50-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-51-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-41-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852550-42-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852550-43-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(ethylthio)ethyl)-6-[4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-44-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-45-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-52-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-53-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)



RN 852550-54-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-55-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-56-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852550-57-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




RN 852550-58-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-ethylthioethyl)- (CA INDEX NAME)



RN 852550-59-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-60-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




RN 852550-61-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852550-68-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-69-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-70-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3,5-dichlorobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-71-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(methoxypropyl)-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-72-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2,4-dichlorobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852550-62-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-64-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852550-65-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-66-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromobenzoyl)-1-piperazinyl]-N-hexyl- (CA INDEX NAME)




RN 852550-67-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852550-73-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-74-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-75-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-76-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-[(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-77-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(2-bromobenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 852550-78-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-79-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-[4-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-80-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-81-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(3-methoxypropyl)- (CA INDEX NAME)




RN 852550-82-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-83-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-89-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852550-90-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-[3-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852550-91-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxy)propyl]- (CA INDEX NAME)




RN 852550-92-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-93-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-(4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)




121 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852550-84-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852550-85-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)



RN 852550-86-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852550-87-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-hexyl-
(CA INDEX NAME)




```
RN      852550-88-0  HCAPLUS
CN      3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(3-
methoxypropyl)- (CA INDEX NAME)
```

121 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 852550-94-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-hexyl-
(CA INDEX NAME)




RN 852550-95-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-{3-(trifluoromethyl)benzoyl}-1-piperazinyl]- (CA INDEX NAME)




```
RN 852550-96-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(2-
methylbutyl)- (CA INDEX NAME)
```



RN 852550-97-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



```
RN 852550-98-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-[2-(trifluoromethyl)benzoyl]-1-
piperazinyl]- (CA INDEX NAME)
```




```


RN      852550-99-3  HCAPLUS
CN      3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(4-(trifluoromethyl)benzoyl)-
        1-piperazinyl]-  (CA INDEX NAME)

```


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852551-00-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-(1-methylbutyl)- (CA INDEX NAME)




RN 852551-01-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dimethylbenzoyl)-1-piperazinyl]-N-(2-methylbutyl)- (CA INDEX NAME)



RN 852551-02-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-03-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-bromobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852551-04-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylethoxypropyl)-6-[4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl]-N-[3-(1-methylethoxypropyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)


RN 852551-09-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-10-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-11-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-12-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-13-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-[2-(ethylthio)ethyl]- (CA INDEX NAME)




RN 852551-14-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852551-05-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-06-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-07-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-08-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852551-15-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-16-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxypropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-17-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-pentyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-19-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852551-22-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)





RN 852551-23-6 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-24-7 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-25-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)




RN 852551-30-5 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 852551-31-6 HCAPLUS
 CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-34-9 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 852551-35-0 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-36-1 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1,3-dimethylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-38-3 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-39-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-41-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-ethoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-42-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-43-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-44-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-methoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-50-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-51-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(ethylthio)ethyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-52-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(dimethylamino)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




IT 852551-54-3P, N-(2-Cyclopropylethyl)-6-[4-(3-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-55-4P, N-(1-Methyl-3-phenylpropyl)-6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-56-5P, N-(1-Methyl-2-phenylethyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-57-6P, 6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-59-8P, 6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852551-61-2P, 6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide 852551-64-5P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-65-6P, N-(1-Methyl-3-phenylpropyl)-6-[4-(naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-45-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-butyl-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-46-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-butoxypropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-47-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methylbutyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-48-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1-methylethoxy)propyl]-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-49-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-hexyl-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


852551-66-7P, 6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-phenethylnicotinamide 852551-69-0P, N-(1-Methyl-3-phenylpropyl)-6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-70-3P, N-(2-(3H-Imidazol-4-yl)ethyl)-6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-71-4P, 6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-[(Tetrahydrofuran-2-yl)methyl]nicotinamide 852551-72-5P, 6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]-N-[(Tetrahydrofuran-2-yl)methyl]nicotinamide 852551-73-6P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-84-9P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-76-9P, 6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-77-0P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-78-1P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(Naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide 852551-83-8P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2-Fluoro-4-methylbenzoyl)piperazin-1-yl]nicotinamide 852551-84-9P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]nicotinamide 852551-85-0P, N-(3-Phenylpropyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-86-1P, N-(4-Phenylbutyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-87-2P, N-(3-Phenylpropyl)-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-88-3P, 6-[4-(2-Bromo-3-phenylpropyl)piperazin-1-yl]-N-(2-methyl-3-phenylpropyl)nicotinamide 852551-89-4P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(5-phenylpentyl)nicotinamide 852551-90-7P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-91-8P, N-(4-Phenylbutyl)-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-92-9P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide 852551-93-0P, N-Phenethyl-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-94-1P, N-Phenethyl-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-95-2P, N-Phenethyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-96-3P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-97-4P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852551-98-5P, N-(1-Methyl-3-phenylpropyl)-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852551-99-6P, N-[2-(3H-Imidazol-4-yl)ethyl]-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-00-2P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-01-3P, N-[2-(3H-Imidazol-4-yl)ethyl]-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-02-4P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-03-5P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-04-6P, N-(Tetrahydrofuran-2-yl)methyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-05-7P, N-[2-(3H-Imidazol-4-yl)ethyl]-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-06-8P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-07-9P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-08-0P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]nicotinamide 852552-09-1P, N-(4-Phenylbutyl)-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-10-4P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852552-11-5P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide 852552-12-6P, N-[3-(Imidazol-1-yl)propyl]-6-[4-(4-Trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852552-43-7P, 6-[4-(Naphthalen-2-yl)carbonyl]piperazin-1-yl]-N-pentylnicotinamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOB (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of nicotinamide derivs. and their use as therapeutic agents for treating stearyl-CoA desaturase-mediated diseases)

RN 852551-54-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-cyclopropylethyl)-6-[4-(3-


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-55-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-2-phenylethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-56-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-2-phenylethyl)-6-[4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl]- (CA INDEX NAME)



RN 852551-57-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852551-59-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



RN 852551-65-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)




RN 852551-66-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 852551-69-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-61-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-(3-phenylpropyl)- (CA INDEX NAME)




RN 852551-64-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)

PAGE 1-A




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-70-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 852551-71-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 852551-72-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(1-naphthalenylcarbonyl)-1-piperazinyl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A



RN 852551-73-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-(1H-imidazol-1-yl)propyl)-6-(4-(2-naphthalenylcarbonyl)-1-piperazinyl)- (CA INDEX NAME)



RN 852551-74-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3H-imidazol-5-yl)ethyl)-6-(4-(2-naphthalenylcarbonyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-75-8 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(4-(2-naphthalenylcarbonyl)-1-piperazinyl)-N-(2-phenylethyl)- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A




RN 852551-83-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3-chlorophenyl)ethyl)-6-(4-(2-fluoro-4-methylbenzoyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-84-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3-chlorophenyl)ethyl)-6-(4-(2,5-dichlorobenzoyl)-1-piperazinyl)- (CA INDEX NAME)



RN 852551-85-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-(4-(4-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-86-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-(4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-87-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-phenylpropyl)-6-(4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 852551-76-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(4-(2-naphthalenylcarbonyl)-1-piperazinyl)-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852551-77-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3-chlorophenyl)ethyl)-6-(4-(2-naphthalenylcarbonyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-78-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(3-(1H-imidazol-1-yl)propyl)-6-(4-(1-naphthalenylcarbonyl)-1-piperazinyl)- (CA INDEX NAME)


PAGE 1-A




L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 852551-88-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(4-(2-bromobenzoyl)-1-piperazinyl)-N-(2-methyl-3-phenylpropyl)- (CA INDEX NAME)




RN 852551-89-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(4-(2-bromo-5-methoxybenzoyl)-1-piperazinyl)-N-(5-phenylpentyl)- (CA INDEX NAME)



RN 852551-90-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(3-chlorophenyl)ethyl)-6-(4-(2-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-91-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-(4-(3-(trifluoromethyl)benzoyl)-1-piperazinyl)- (CA INDEX NAME)




RN 852551-92-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(4-(3,5-dichlorobenzoyl)-1-piperazinyl)-N-(1-methyl-3-phenylpropyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852551-93-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-94-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-[2-(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852551-95-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-phenylethyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-96-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-97-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(3,5-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852551-98-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-(1-methyl-3-phenylpropyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852551-99-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-(2-(1H-imidazol-5-yl)ethyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-00-2 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-01-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-02-4 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852552-03-5 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-04-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[(tetrahydro-2-furanyl)methyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-05-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(1H-imidazol-5-yl)ethyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-06-8 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-07-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-08-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(3-chlorophenyl)ethyl]-6-[4-[(3,5-dichlorobenzoyl)-1-piperazinyl]- (CA INDEX NAME)


L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 852552-09-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenylbutyl)-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)




RN 852552-10-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,4-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)



RN 852552-11-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2,5-dichlorobenzoyl)-1-piperazinyl]-N-(4-phenylbutyl)- (CA INDEX NAME)




RN 852552-12-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(trifluoromethyl)benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 852552-63-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-(2-naphthalenylcarbonyl)-1-piperazinyl]-N-pentyl- (CA INDEX NAME)

L21 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:29200 HCAPLUS

DN 142:134463

TI Preparation of 2-phenyl-N-(pyridin-3-yl)-N-methylisobutyramide derivatives

as dual NK1/NK3 antagonists for treating schizophrenia

IN Hoffmann, Torsten; Koblet, Andreas; Peters, Jens-Uwe; Schnider, Patrick;

Sleight, Andrew; Stadler, Heinz

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 374 pp.

CODEN: PIXXD2



DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005002577	A1	20050113	2004WO-EP0006929	20040625 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
PM: BW, CH, GM, KE, LG, MM, ME, NA, SD, SL, SZ, TG, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004253267	A1	20050113	2004AU-000253267	20040625 <--
CA-----2530886	A1	20050113	2004CA-002530886	20040625 <--
EP-----1643988	A1	20060412	2004EP-000740337	20040625 <--
EP-----1643988	B1	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR--2004012291	A	20060919	2004BR-00012291	20040625 <--
CN-----1852712	A	20061025	2004CN-080025360	20040625 <--
AT-----371451	T	20070915	2004AT-000740337	20040625 <--
ES-----2291891	T3	20080301	2004ES-000740337	20040625 <--
US--2005090533	A1	20050428	2004US-000884707	20040702 <--
NO--2005006007	A	20060119	2005NO-000006007	20051216 <--
IN--2006CN00020	A	20070608	2006IN-CN0000020	20060103 <--
KR-----744859	B1	20070801	2006KR-000700167	20060103 <--
MX--2006PA00192	A	20060411	2006MX-PA00000192	20060105 <--
PRAI 2003EP-000014513	A	20030703		
2004WO-EP0006929	W	20040625		
OS MARPAT 142:134463				
GI				

L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The invention is directed to the use of compds. of formula I [wherein R1 = (un)substituted aryl; R2, R3 = independently H, halo, alkyl, alkoxy, OCHF2, OCH2F, OCF3, or CF3; R4, R5 = independently H, CHO, (CH2)oS(O)p-alkyl, etc.; o = 0-3; p = 0-2; or R4R5 form an (un)substituted ring with -(CH2)3-5-, -(CH2)1,2,3-O-(CH2)2-, -CH2CH:CHCH2-, etc.;] and their pharmaceutically active acid addition salts as dual neurokinin NK1/NK3 antagonists useful in the treatment of schizophrenia. The invention discloses 421 preps. of title compds. For example, II was prepared, in 2 steps, by acylation of N-[6-chloro-4-(2-chlorophenyl)pyridin-3-yl]methylamine (preparation given) with 2-(3,5-dichlorophenyl)-2-methylpropanoyl chloride (preparation given) and amination with (L)-prolinol. II bound to NK1 and NK3 receptors with pKi value of 8.47 and 9.05, resp.


II 825639-95-OP, 2-[3,5-Bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)piperazin-1-yl]pyridin-3-yl]-N-methylisobutyramide 825643-36-1P, (S)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[6-[4-(cyclopropylcarbonyl)-2-hydroxymethylpiperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-N-methylisobutyramide

PL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(pyridin-3-yl)-N-methylisobutyramide derivs. as dual NK1/NK3 antagonists for treating schizophrenia)

RN 825639-95-0 HCAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)-1-piperazinyl]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)




RN 825643-36-1 HCAPLUS

CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

L21 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
RN 2002:775262 HCAPLUS
DN 138:187738

TI 2-[4-(p-acetamidophenylcarbonyl)piperazin-1-yl]-3-(N-
arythioureidocarbonyl)pyridines as antibacterial agents
AU Patel, N. B.; Bhagat, P. R.
CS Department of Chemistry, South Gujarat University, Surat, 395 007, India
SO Indian Journal of Heterocyclic Chemistry (2002), 12(1), 83-84
CODEN: IJCHEX; ISSN: 0971-1627

PB Prof. R. S. Varma
DT Journal
LA English
AS CASREACT 138:187738

AB The title compds. were prepared in 54-75% yields from 2-chloro-3-
(arythioureidocarbonyl)pyridines and 4-(p-acetamidophenylcarbonyl)piperaz
ine. The antibacterial activity of the title compds. was tested against
Staphylococcus aureus and Escherichia coli. Active to highly active
activity was observed

IT 499131-82-7P 499131-83-8P 499131-84-9P

499131-85-0P 499131-86-1P 499131-87-2P

499131-88-3P 499131-89-4P 499131-90-7P

499131-91-8P 499131-92-9P 499131-93-0P


PL PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation)

(Preparation and antibacterial activity of [(acetamidophenylcarbonyl)piperaz
inyl (N-arythioureidocarbonyl)pyridines)


RN 499131-82-7 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-
[(phenylamino)thioxomethyl]- (CA INDEX NAME)




RN 499131-83-8 HCAPLUS

CN Benzoic acid, 4-[[[2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-3-
pyridinyl]carbonyl]amino]thioxomethyl]amino]- (CA INDEX NAME)




RN 499131-84-9 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[2-
methoxyphenyl]amino]thioxomethyl]- (CA INDEX NAME)




L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 499131-89-4 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[2-
nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-90-7 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[3-
nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)



RN 499131-91-8 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[4-
nitrophenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-92-9 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[3-
chlorophenyl]amino]thioxomethyl]- (CA INDEX NAME)




L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 499131-85-0 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[4-
methoxyphenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-86-1 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[2-
methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)



RN 499131-87-2 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[3-
methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)




RN 499131-88-3 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[4-
methylphenyl]amino]thioxomethyl]- (CA INDEX NAME)




L21 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 499131-93-0 HCAPLUS

CN 3-Pyridinecarboxamide, 2-[4-[4-(acetamino)benzoyl]-1-piperazinyl]-N-[[4-
chlorophenyl]amino]thioxomethyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SYN (Continued)
 AN 2002:314905 HCAPLUS
 DN 136:1325568
 TI Preparation of 2-phenyl-4-piperazinylpiperidine-1-carboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS disorders
 Alvaro, Giuseppe; Di Fabio, Romano; Maragni, Paolo; Tampieri, Marsia;
 Tranquillini, Maria Elvira
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2002032867	A1	20020425	2001WO-GB0004580	20011012 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, ES, FI, FR, GB, GR, GE, GM, GU, HK, HU, ID, IL, IN, JP, KE, KG, KP, KR, KS, LC, LM, LR, LS, LT, LU, LV, MA, MD, MG, MK, MM, MN, MX, MY, NZ, NI, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LE, MW, ME, SD, SL, SE, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SH, TD, TG				
CA-----2425876	A1	20020425	2001CA-002425876	20011012 <--
AU-2001095723	A	20020429	2001AU-00095723	20011012 <--
EP-----1326832	A1	20030716	2001EP-000976453	20011012 <--
EP-----1326832	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR-2001014637	A	20030930	2001BR-000014637	20011012 <--
JP-2004511544	T	20040415	2003JP-000536051	20011012 <--
JP-----3940359	B2	20070704		
AT-----278669	T	20041015	2001AT-000976453	20011012 <--
PT-----1326832	T	20050331	2001PT-000976453	20011012 <--
ES-----2227287	T3	20050401	2001ES-000976453	20011012 <--
EP-----1524266	A1	20050420	2004EP-000077714	20011012 <--
EP-----1524266	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR				
NZ-----525091	A	20050429	2001NZ-000525091	20011012 <--
AU-2001295723	B2	20050526	2001AU-000295723	20011012 <--
AT-----355271	T	20060315	2004AT-000077714	20011012 <--
HU-2003001459	A2	20060928	2003HU-000001459	20011012 <--
RU-2003001459	A3	20071128		
EP-----1752449	A1	20070214	2006EP-000122021	20011012 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
IN-----2282794	T3	20071016	2004IN-000077714	20011012 <--
ES-2003MNO0366	A	20050211	2003IN-MNO000366	20030403 <--
NO-2003001561	A	20030614	2003NO-000001561	20030407 <--
NO-----324468	B1	20071022		
ZA-2003002803	A	20040421	2003ZA-000002803	20030410 <--
MX-2003PA03536	A	20030807	2003MX-PA0003536	20030421 <--
US-20040014770	A1	20040122	2003US-000398264	20030729 <--
US-----1113092	B2	20060210		
HK-----1058788	B1	20050527	2004HK-000100241	20040113 <--
US-20050137208	A1	20050623	2004US-000994605	20041122 <--
US-----706702	B2	20060613		
AU-2005204234	A1	20050915	2005AU-000204234	20050824 <--
US-20060142302	A1	20060629	2006US-000358631	20060221 <--
US-----7294630	B2	20071113		
US-2008021041	A1	20080814	2007US-000865211	20071001 <--
PRAI 2000GB-000025354	A	20001017	<--	
2001EP-000976453	A3	20011012	<--	
2004EP-000077714	A3	20011012	<--	
2001WO-GB0004580	W	20011012	<--	
2003US-000398264	A1	20030729	<--	
2004US-000994605	A1	20041122	<--	
2006US-000358631	A1	20060221	<--	

L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SYN (Continued)
 AN 414910-46-6 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 414910-48-8 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SYN (Continued)
 OS MAPPAT 136:1325568
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = halo or alkyl; R1 = alkyl; R2 = H or alkyl; R3 = H or alkyl; R4 = CF3; R5 = H, alkyl, or COP6; R6 = (cycloalkyl or (di)alkylamino; m = 0-3; n = 1-3; and pharmaceutically acceptable salts and solvates thereof] were prepared as tachykinin antagonists. For example, reductive amination 2-(R)-[4-fluoro-2-methylphenyl]-2-(R)-[4-fluoro-2-methylphenyl]piperidine-1-carboxylic acid N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methanamide (preparation given) with 1-acetyl-piperazine using sodium triacetoxycarbonylhydride gave a mixture of diastereomers. 4(R)-II and 4-(S)-II were separated by flash chromatog. and the latter converted to its HCl salt. In a neurokinin 1 (NK1) receptor binding affinity assay, 4-(S)-II [NK1] displaces [3H]-substance P from recombinant human NK1 receptors expressed in Chinese Hamster Ovary cell membranes with pK_i of 9.36. In addition, oral administration of 4-(S)-II-HCl to gerbils inhibited foot tapping induced by an NK1 agonist with ED₅₀ of 0.05 mg/kg. I are useful for the treatment of CNS disorders, pain, sleep disorders, cognitive disorders, substance abuse, allergic disorders, emesis, gastrointestinal disorders, and depressive states (no data).

IT 414910-47-7P, 4-(S)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-fluoro-2-methylphenyl]piperidine-1-carboxylic acid N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

IT 414910-46-6P, 4-(R)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-fluoro-2-methylphenyl]piperidine-1-carboxylic acid N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamide 414910-48-8P, 4-(S)-[4-(4-Cyclopropylpiperazin-1-yl)-2-(R)-[4-fluoro-2-methylphenyl]piperidine-1-carboxylic acid N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N-methylamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

L21 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS ON SYN
 AN 2001:265388 HCAPLUS
 DN 134:295742
 TI Preparation of a combinatorial library of pyridine carboxamides and sulfonamides for various pharmaceutical uses
 IN Chen, Yueshi; Lang, Hengyuan; Pei, Yazhong
 PA Treps Biosciences, Inc., USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2001025203	A1	20010412	2000WO-US00021204	20000803 <--
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US-----6677452	B1	20040113	1999US-000410142	19990930 <--
EP-----1218343	A1	20020703	2000EP-000953818	20000803 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI 1999US-000410142	A	19990930	<--	
2000WO-US00021204	W	20000803	<--	
OS MAPPAT 134:295742				
GI				

AB A combinatorial library of pyridine carboxamides and sulfonamides, such as I (R1, R2, R3, R4 = H, OH, NO2, CN, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyloxy, phenylalkyl, heterocyclylalkyl, etc.; X=NR7R8; R6 = H, alkyl, alkenyl, Ph, naphthyl, phenylalkyl, heterocyclylalkyl, heteroaryl, heterocyclyl, etc.; R7, R8 = H, alkyl, heterocyclyl, cycloalkyl, cycloalkenyl, phenylalkyl, heterocyclylalkyl, etc.; D, E = NH, heteroarylene, heterocyclylene, etc.; W = alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, heteroarylene, etc.; X = CO, SO2), were prepared via solid-phase synthesis for a variety of pharmaceutical uses. Thus, pyridine carboxamide II was prepared starting from a primary amine R7NH2 (R7 = alkyl, alkenyl, etc.), 6-chloronicotinic acid, piperazine, and benzoic acid with the use of Merrifield resin. The prepared pyridine carboxamides and sulfonamides were tested for melanocortin receptor binding, antibacterial activity, and penile erection augmentation.

IT 334002-42-5DP, N-substituted derivative
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of a combinatorial library of pyridine carboxamides and sulfonamides via Merrifield solid-phase synthesis for a variety of pharmaceutical uses)

RN 334002-42-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-(4-benzoyl-1-piperazinyl)- (CA INDEX NAME)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:34:44 ON 29 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 146 tot
```

146 ANSWER 1 OF 1 USPATFULL ON STN
 AN 2005118601 USPATFULL
 TI Nicotinamide derivatives and their use as therapeutic agents
 IN Pu, Jian-Min, Burnaby, CANADA
 Kothumuri, Vishnumurthy, Burnaby, CANADA
 Sun, Shaoyi, Vancouver, CANADA
 Winther, Michael D., Vancouver, CANADA
 Fine, Richard M., Ridgewood, NJ, UNITED STATES
 Harvey, Daniel P., San Diego, CA, UNITED STATES
 Klebanov, Boris, Demarest, NJ, UNITED STATES
 Gray-Keller, Mark P., Madison, WI, UNITED STATES
 Gschwend, Heinz W., Santa Rosa, CA, UNITED STATES
 Li, Wenbao, San Diego, CA, UNITED STATES
 PI US-20050119251 A1 20050602
 AI 200405-00085901 A1 20040706 (10)
 RLI Continuation-in-part of Ser. No. 2002US-000326210, filed on 20 Dec 2002,
 PENDING
 PRAI 2002US-000343516P 20011221 (60) <--
 2002US-000394506P 20020709 (60) <--
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
 SEATTLE, WA, 98104-7092, US
 CLMN Number of Claims: 61
 ECI Exemplary Claim: 1
 DWRN 1 Drawing Page(s)
 LN.CNT 4294

CA INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods of treating an SCD-mediated disease or condition in a mammal,
 preferably a human, are disclosed, wherein the methods comprise
 administering to a mammal in need thereof a compound of formula (I):
 #5STR1# where m, n, p, V, R1, R2, R3, R4, R5 and R6 are defined
 herein. Pharmaceutical compositions comprising the compounds of formula
 (I) are also disclosed.

CA INDEXING IS AVAILABLE FOR THIS PATENT.

II 252548-31-3P, N-(2-cyclopropylethyl)-2-methoxy-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide
 (drug candidate; preparation of nicotinamide derivs. and their use as
 therapeutic agents for treating stearyl-CoA desaturase-mediated
 diseases)
 II 361209-76-9P, N-[3-(imidazol-1-yl)propyl]-6-[4-(2,3,4,5-
 tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361209-78-2P,
 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-
 yl)propyl]nicotinamide 361209-80-5P, 6-[4-(2,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide
 361209-81-8P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[3-
 (imidazol-1-yl)propyl]nicotinamide 361209-88-3P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-
 yl)propyl]nicotinamide 361210-17-5P, 6-[4-(2,4-
 Bromobenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-yl)propyl]nicotinamide
 361450-94-4P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2,3,4,5-
 tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 361451-03-8P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[2-(3-
 chlorophenyl)ethyl]nicotinamide 361451-43-6P,
 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-[2-(3-
 chlorophenyl)ethyl]nicotinamide 361452-19-2P
 N-(2-(3H-Imidazol-4-yl)ethyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-
 1-yl]nicotinamide 361452-33-7P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-Imidazol-4-yl)ethyl]nicotinamide
 361452-34-8P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-
 imidazol-4-yl)ethyl]nicotinamide 361452-43-9P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-[2-(3H-Imidazol-4-
 yl)ethyl]nicotinamide 361452-60-0P, 6-[4-(2,4-
 Dimethylbenzoyl)piperazin-1-yl]-N-[2-(3H-Imidazol-4-yl)ethyl]nicotinamide
 361452-63-3P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-[2-(3H-
 imidazol-4-yl)ethyl]nicotinamide 361453-93-2P, N-(1-Methyl-3-phenylpropyl)-
 6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-
 yl]nicotinamide 361454-25-3P, 6-[4-(2,4-
 Dimethylbenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide
 361464-05-3P, N-Pentyl-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-

146 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 1-yl]nicotinamide 361464-25-7P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-pentyl]nicotinamide 361464-27-9P
 , 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-pentyl]nicotinamide
 361464-30-4P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-
 pentyl]nicotinamide 361464-42-8P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-pentyl]nicotinamide 361465-01-2P
 , 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-pentyl]nicotinamide
 361465-07-8P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-
 pentyl]nicotinamide 361466-83-3P, N-(3-Butoxypropyl)-6-[4-
 (2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide
 361466-92-5P, N-(3-Butoxypropyl)-6-[4-(2,4-
 dichlorobenzoyl)piperazin-1-yl]nicotinamide 361466-96-8P,
 N-(3-Butoxypropyl)-6-[4-(2,5-dichlorobenzoyl)piperazin-1-yl]nicotinamide
 361466-99-1P, N-(3-Butoxypropyl)-6-[4-(2,5-
 dichlorobenzoyl)piperazin-1-yl]nicotinamide 361467-39-8P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-
 butoxypropyl)nicotinamide 361467-87-0P, N-(3-Butoxypropyl)-6-[4-
 (2,4-dimethylbenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide
 361526-44-5P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
 phenylpropyl)nicotinamide 361526-54-7P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide
 361526-74-1P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
 phenylpropyl)nicotinamide 361538-99-0P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-(1-methyl-3-phenylpropyl)nicotinamide
 503281-17-2P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-
 phenethyl]nicotinamide 361980-14-5P, 6-[4-(2-
 Bromobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide
 361989-24-4P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-
 [(tetrahydrofuran-2-yl)methyl]nicotinamide 361991-32-4P,
 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-phenylpropyl)nicotinamide
 503281-45-0P, N-Butyl-6-[4-(2,4-dichlorobenzoyl)piperazin-1-
 yl]nicotinamide 503281-66-1P, N-Butyl-6-[4-(2,5-
 dichlorobenzoyl)piperazin-1-yl]nicotinamide 503281-67-2P,
 N-Butyl-6-[4-(3,5-dichlorobenzoyl)piperazin-1-yl]nicotinamide
 503281-81-0P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-
 butyl]nicotinamide 503282-19-7P, N-Butyl-6-[4-(2,4-
 dimethylbenzoyl)piperazin-1-yl]nicotinamide 503317-33-7P,
 N-(3-Methylbutyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-
 yl]nicotinamide 503317-38-2P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide
 503317-39-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 methylbutyl)nicotinamide 503317-40-8P, 6-[4-(2,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide
 503317-47-3P, 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-
 methylbutyl)nicotinamide 503318-61-4P, N-(3-
 Dimethylaminopropyl)-6-[4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-
 yl]nicotinamide 503318-65-8P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-(3-dimethylaminopropyl)nicotinamide
 503318-66-9P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 dimethylaminopropyl)nicotinamide 503318-74-9P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(3-
 dimethylaminopropyl)nicotinamide 503318-85-3P,
 N-(3-Dimethylaminopropyl)-6-[4-(2,4-dimethylbenzoyl)piperazin-1-
 yl]nicotinamide 503324-63-6P, 6-[4-(2,3,4,5-
 Tetrafluorobenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 503324-68-3P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 503324-76-3P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 503324-96-7P, 6-[4-(2,4-
 Dimethylbenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 503324-98-9P, 6-[4-(2,4-
 Bromobenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-yl)methyl]nicotinamide
 503325-91-5P, N-(3-Ethoxypropyl)-6-[4-(2,3,4,5-
 tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503325-96-0P,
 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide

146 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 503325-97-1P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 ethoxypropyl)nicotinamide 503326-04-3P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide
 503326-24-7P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(3-
 ethoxypropyl)nicotinamide 503326-27-0P, 6-[4-(2-
 Bromobenzoyl)piperazin-1-yl]-N-(3-ethoxypropyl)nicotinamide
 503326-86-1P, N-(4-Phenylbutyl)-6-[4-(2,3,4,5-
 tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 503327-14-8P,
 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-(4-phenylbutyl)nicotinamide
 503327-17-1P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(4-
 phenylbutyl)nicotinamide 503421-63-8P, N-(1,3-Dimethylbutyl)-6-
 [4-(2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide
 503421-73-4P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-
 dimethylbutyl)nicotinamide 503421-75-8P, 6-[4-(2,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-dimethylbutyl)nicotinamide
 503421-77-0P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(1,3-
 dimethylbutyl)nicotinamide 503421-94-1P,
 6-[4-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(1,3-
 dimethylbutyl)nicotinamide 503422-32-0P, 6-[4-(2,4-
 Dimethylbenzoyl)piperazin-1-yl]-N-(3,3-dimethylbutyl)nicotinamide
 503422-36-4P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(1,3-
 dimethylbutyl)nicotinamide 503433-15-4P, N-Phenethyl-6-[4-
 (2,3,4,5-tetrafluorobenzoyl)piperazin-1-yl]nicotinamide
 503453-18-7P, 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-
 phenethyl]nicotinamide 503453-26-7P, 6-[4-(2-Bromo-5-
 methoxybenzoyl)piperazin-1-yl]-N-phenethyl]nicotinamide
 503453-44-9P, 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-
 phenethyl]nicotinamide 503453-47-2P, 6-[4-(2-
 Bromobenzoyl)piperazin-1-yl]-N-phenethyl]nicotinamide 504417-35-0P
 , 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-methylbutyl)nicotinamide
 504417-38-3P, 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 dimethylaminopropyl)nicotinamide 504417-46-3P,
 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 504418-10-4P, 6-[4-(2,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-phenethyl]nicotinamide
 504423-73-4P, 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-
 dimethylaminopropyl)nicotinamide 504426-87-3P,
 6-[4-(2,4-Dimethylbenzoyl)piperazin-1-yl]-N-[3-(imidazol-1-
 yl)propyl]nicotinamide 504428-07-3P, N-Butyl-6-[4-(2,3,4,5-
 tetrafluorobenzoyl)piperazin-1-yl]nicotinamide 504429-46-3P,
 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-[2-(3H-Imidazol-4-
 yl)ethyl]nicotinamide 852548-17-5P, N-(2-Cyclopropylethyl)-6-[4-
 (5-Fluoro-2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide
 852548-21-1P, N-(2-Cyclobutylethyl)-6-[4-(5-Fluoro-2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-22-2P
 , N-(3-Cyclopropylpropyl)-6-[4-(5-Fluoro-2-trifluoromethylbenzoyl)piperaz-
 in-1-yl]nicotinamide 852548-24-4P, 6-[4-(5-Fluoro-2-
 trifluoromethylbenzoyl)piperazin-1-yl]-N-(4-methylpentyl)nicotinamide
 852548-26-6P, N-(3,3-Dimethylbutyl)-6-[4-(5-Fluoro-2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-28-4P
 , N-(2-Cyclopropylethyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852548-39-1P, 2-Oxo-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]-2,4-dihydropyridine-3-carboxylic
 Acid (2-cyclopropylethyl)nicotinamide 852548-47-3P,
 6-[4-(2-Phenylcyclopropylcarbonyl)piperazin-1-yl]-N-(3-
 phenylpropyl)nicotinamide 852548-58-4P, N-Butyl-6-[4-(2-
 mercaptobenzoyl)piperazin-1-yl]nicotinamide 852548-65-3P,
 N-(2-Methylbutyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852548-67-5P, N-(3-Methylbutyl)-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide hydrochloride
 852548-69-7P, N-(2,3-Methylbutyl)-4-trifluoromethyl-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-71-1P
 , 2-Chloro-5-fluoro-N-(3-methylbutyl)-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852548-73-3P,
 2-Chloro-N-(3-methylbutyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852548-81-3P, N-(2-(3-Chlorophenyl)ethyl)-6-[4-
 (2,4-dichlorobenzoyl)piperazin-1-yl]nicotinamide 852548-83-5P,
 6-(2-Oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl)-N-(3-
 phenylpropyl)nicotinamide 852548-85-7P, N-(3-Methylbutyl)-6-[2-
 oxo-4-(2-trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide
 852548-91-5P, N-Butyl-6-[4-(2-Phenylcyclopropylcarbonyl)piperazi-
 n-1-yl]nicotinamide 852548-92-8P, N-(3-Methylbutyl)-6-[4-
 (naphthalen-1-yl)carbonyl]piperazin-1-yl]nicotinamide
 852548-94-8P, N-[2-(3-Chlorophenyl)ethyl]-6-[4-(2-

146 ANSWER 1 OF 1 USPATFULL ON STN (Continued)
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-33-2P, N-(2-Bromo-5-methoxybenzoyl)piperazin-1-yl]-N-(2-
 ethylsulfonyl)ethyl]nicotinamide 852549-05-4P,
 N-(3-Phenylpropyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852549-12-2P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-(3-methyl-3-phenylpropyl)nicotinamide
 852549-15-6P, N-(1,3-Dimethylbutyl)-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852549-17-8P
 , 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-methoxypropyl)nicotinamide
 852549-77-0P, N-Pentyl-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852549-89-4P, N-(3-Ethoxypropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-91-8P, N-(2-Ethylsulfonyl)ethyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-93-0P, N-(1,3-Dimethylbutyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-94-8P, N-(2-Ethylsulfonyl)ethyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-95-2P, N-(3-Methylbutyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-97-4P, N-(3-Methoxypropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852549-99-6P, N-(3-Butoxypropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-01-7P, N-(3-Dimethylaminopropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-03-9P, N-(3-Isopropoxypropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-05-1P, N-(3-Methylbutyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-07-3P, N-Butyl-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-
 yl]nicotinamide 852550-09-5P, N-Hexyl-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-11-9P, N-(2-Methylbutyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-14-2P, N-(4-Phenylbutyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-15-7P, N-(1-Methyl-3-phenylpropyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-19-7P, N-Phenethyl-6-[4-(2-phenylcyclopropylcarbonyl)piper-
 azin-1-yl]nicotinamide 852550-21-1P, 6-[4-(2-
 Phenylcyclopropylcarbonyl)piperazin-1-yl]-N-[(tetrahydrofuran-2-
 yl)methyl]nicotinamide 852550-23-3P, N-[2-(3H-Imidazol-4-
 yl)ethyl]-6-[4-(2-phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-25-5P, N-(3-Imidazol-1-yl)propyl)-6-[4-(2-
 phenylcyclopropylcarbonyl)piperazin-1-yl]nicotinamide
 852550-38-0P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 methoxypropyl)nicotinamide 852550-41-5P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)ethyl]nicotinamide
 852550-42-6P, N-(3-Ethoxypropyl)-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-43-7P
 , N-(2-Ethylsulfonyl)ethyl)-6-[4-(3-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852550-44-4P, 6-[4-(3,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-(3-Isopropoxypropyl)nicotinamide
 852550-45-9P, N-(3-Methylbutyl)-6-[4-(3-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-46-0P
 , 6-[4-(2,4-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 isopropoxypropyl)nicotinamide 852550-47-1P,
 N-(3-Ethoxypropyl)-6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852550-48-9P, N-Butyl-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-50-6P
 , 6-[4-(2-Bromobenzoyl)piperazin-1-yl]-N-(3-Isopropoxypropyl)nicotinamide
 852550-51-7P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 isopropoxypropyl)nicotinamide 852550-52-8P,
 N-(3-Butoxypropyl)-6-[4-(4-trifluoromethylbenzoyl)piperazin-1-
 yl]nicotinamide 852550-53-9P, 6-[4-(2,5-
 Dichlorobenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)ethyl]nicotinamide
 852550-54-0P, N-(3-Butoxypropyl)-6-[4-(2-
 trifluoromethylbenzoyl)piperazin-1-yl]nicotinamide 852550-55-1P
 , 6-[4-(2,5-Dichlorobenzoyl)piperazin-1-yl]-N-(3-
 methoxypropyl)nicotinamide 852550-56-2P, 6-[4-(2,4-
 Dichlorobenzoyl)piperazin-1-yl]-N-(2-methylbutyl)nicotinamide
 852550-57-3P, 6-[4-(3,5-Dichlorobenzoyl)piperazin-1-yl]-N-(2-
 methylbutyl)nicotinamide 852550-58-4P, 6-[4-(2,4-
 Dimethylbenzoyl)piperazin-1-yl]-N-(2-ethylsulfonyl)ethyl]nicotinamide
 852550-59-5P, N-(1,3-Dimethylbutyl)-6-[4-(3-

=> d bib abs hitstr 147 tot

L47 ANSWER 1 OF 9 USPATFULL ON STN
 AN 2008:33860 USPATFULL
 TI Chemical Compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paola, Verona, ITALY
 Tampieri, Maria, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-2008023041 A1 20080234
 AI 2007US-000865211 A1 20071001 (11)
 RLI Continuation of Ser. No. 2006US-000358631, filed on 21 Feb 2006,
 GRANTED, Pat. No. US-----7294630 Continuation of Ser. No.
 2004US-00094605, filed on 22 Nov 2004, GRANTED, Pat. No. US-----7060702
 Continuation of Ser. No. 2003US-000398264, filed on 29 Jul 2003,
 GRANTED, Pat. No. US-----719092 A 371 of International Ser. No.
 2003WO-GB0004580, filed on 12 Oct 2003
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 PS APPLICATION
 LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE
 DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLAIM Number of Claims: 5
 ECL Exemplary claims: 1-13
 DRWN No Drawings
 LN.CNT 1659


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides a method for the treatment of emesis in a
 mammal being treated with an opioid analgesic

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-47-7 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-fluoro-2-
 methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-46-6 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-

L47 ANSWER 2 OF 9 USPATFULL ON STN
 AN 2006:16791 USPATFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paola, Verona, ITALY
 Tampieri, Maria, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20060142302 A1 20060629
 US-----7294630 B2 20071113
 AI 2006US-000358631 A1 20060221 (11)
 RLI Continuation of Ser. No. 2004US-00094605, filed on 22 Nov 2004, PENDING
 Continuation of Ser. No. 2003US-000398264, filed on 29 Jul 2003, PENDING
 A 371 of International Ser. No. 2003WO-GB0004580, filed on 12 Oct 2003
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 PS APPLICATION
 LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE
 DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLAIM Number of Claims: 4
 ECL Exemplary claims: 1-13
 DRWN No Drawings
 LN.CNT 1658
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I): ##STR1##
 wherein


each R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(OR).sub.2;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl)
 or N(C.sub.1-4 alkyl).sub.2; n is zero or an integer from 1 to 3; h is an
 integer from 1 to 3; or a pharmaceutically acceptable salt or solvate
 thereof; compositions containing the same, processes for their
 preparation and methods for their use in the treatment of conditions
 mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)

RN 414910-47-7 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-
 fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanonylpiperazin-1-yl)-2-(R)-(4-fluoro-2-


L47 ANSWER 1 OF 9 USPATFULL ON STN (Continued)
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L47 ANSWER 2 OF 9 USPATFULL ON STN (Continued)
 methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-
 trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; prepn. of piperazinylpiperidinecarboxylic acid
 phenylalkylamides as tachykinin antagonists for treatment of CNS
 disorders)


RN 414910-46-6 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-
 4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-
 methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


L47 ANSWER 3 OF 9 USPTAFULL ON STN
 AN 2005:158998 USPTAFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20050137208 A1 20050623
 US-----7060702 B2 20060613
 AI 2004US-000994605 A1 20041122 (10)
 RLI Continuation of Ser. No. 2003US-00099264, filed on 29 Jul 2003, PENDING
 A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DI Utility
 PS APPLICATION
 LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE
 MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
 CLAM Number of Claims: 80
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2198
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I): ##STR1##
 wherein
 each R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl)
 or N(C.sub.1-4 alkyl).sub.2; n is zero or an integer from 1 to 3; n is an
 integer from 1 to 3; or a pharmaceutically acceptable salt or solvate
 thereof; compositions containing the same, processes for their
 preparation and methods for their use in the treatment of conditions
 mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(S)-[4-(4-cyclopropylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-47-7 USPTAFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)
 Absolute stereochemistry.




IT 414910-46-6P, 4-(R)-(4-Cyclopropylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-

L47 ANSWER 3 OF 9 USPTAFULL ON STN (Continued)
 trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 (tachykinin antagonist; prepn. of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-46-6 USPTAFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)
 Absolute stereochemistry.




RN 414910-48-8 USPTAFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



● HCL


L47 ANSWER 4 OF 9 USPTAFULL ON STN
 AN 2005:105595 USPTAFULL
 TI Dual NK1/NK3 receptor antagonists
 IN Hoffmann, Torsten, Weil am Rhein, GERMANY, FEDERAL REPUBLIC OF
 Koblet, Andreas, Binningen, SWITZERLAND
 Peters, Jens-Uwe, Grenzach-Wyhlen, GERMANY, FEDERAL REPUBLIC OF
 Schnider, Patrick, Oberwil, SWITZERLAND
 Sleight, Andrew, Riedisheim, FRANCE
 Stadler, Heinz, Rheinfelden, SWITZERLAND
 PI US-2005090523 A1 20050428
 AI 2004US-000884707 A1 20040702 (10)
 PRAI 2003EP-000014513 20030703 <--
 DI Utility
 PS APPLICATION
 LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET,
 NUTLEY, NJ, 07110, US
 CLAM Number of Claims: 37
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 13501
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula ##STR1## wherein the substituents are as described herein or a pharmaceutically active acid-addition salt thereof. In particular, the invention provides methods for treating both positive and negative symptoms of schizophrenia through dual inhibition of NK1 and NK3 receptors. The invention also provides novel compounds with formula I and methods for preparing compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 825639-95-0P, 2-[3,5-Bis(trifluoromethyl)phenyl]-N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)piperazin-1-yl]pyridin-3-yl]-N-methylisobutyramide 825643-16-1P, (S)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[6-[4-(cyclopropylcarbonyl)-2-(hydroxymethyl)piperazin-1-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-N-methylisobutanamide
 (drug candidate; preparation of N-(pyridin-3-yl)-N-methylisobutyramide derivs. as dual NK1/NK3 antagonists for treating schizophrenia)
 RN 825639-95-0 USPTAFULL
 CN Benzeneacetamide, N-[4-(2-chlorophenyl)-6-[4-(cyclopropylcarbonyl)-1-piperazinyl]-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)



RN 825643-16-1 USPTAFULL
 CN Benzeneacetamide, N-[6-[(2S)-4-(cyclopropylcarbonyl)-2-(hydroxymethyl)-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,α,α-trimethyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)
 Absolute stereochemistry.

L47 ANSWER 4 OF 9 USPTAFULL ON STN (Continued)



L47 ANSWER 5 OF 9 USPATFULL on STN
 AN 2004:19466 USPATFULL
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PI US-20040014770 A1 20040132
 US-----7119092 B2 20061010
 AI 2003US-000398264 A1 20030729 (10) <--
 2001WO-GB0004580 20011012 <--
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS APPLICATION
 LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE
 MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Formula (1) wherein R represents a halogen atom or a C.sub.1-4 alkyl group; R.sub.1 represents a C.sub.1-4 alkyl group; R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group; R.sub.3 represents hydrogen, or a C.sub.1-4 alkyl group; R.sub.4 represents a trifluoromethyl group; R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6; .sup.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C1-4alkyl).sub.2; n is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenylethyl)-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenylethyl)-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenylethyl)-N-methylamide hydrochloride
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid

L47 ANSWER 6 OF 9 USPATFULL on STN
 AN 2004:9659 USPATFULL
 TI Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
 IN Chen, Yewu, San Diego, CA, United States
 Lang, Hengyuan, San Diego, CA, United States
 Pei, Xuehong, Aliso Viejo, CA, United States
 PA Lion Bioscience AG, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
 PI US-----6677452 B1 20040113
 AI 1999US-000410142 19990930 (9) <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Aulakh, Charanjit S.
 LREP Law Office of David Spolter
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 2602


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pyridine carboxamide or sulfonamide derivative compounds of the following formula: ##STR1## wherein R.sub.1 to R.sub.6 have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing pyridine carboxamide or sulfonamide derivative compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 334002-42-5DP, N-substituted derivative
 (preparation of a combinatorial library of pyridine carboxamides and sulfonamides via Merrifield solid-phase synthesis for a variety of pharmaceutical uses)


RN 334002-42-5 USPATFULL
 CN 3-Pyridinecarboxamide, 6-(4-benzoyl-1-piperazinyl)- (CA INDEX NAME)



L47 ANSWER 5 OF 9 USPATFULL on STN (Continued)
 phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)


RN 414910-46-6 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPATFULL
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L47 ANSWER 7 OF 9 USPAT2 on STN
 AN 2006:167791 USPAT2
 TI Piperazinyl piperidine tachykinin antagonists
 IN Alvaro, Giuseppe, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7294630 B2 20071113
 AI 2006US-000358631 20060221 (11)
 RLI Continuation of Ser. No. 2004US-000994605, filed on 22 Nov 2004, Pat. No. US-----7060702 Continuation of Ser. No. 2004US-000398264, Pat. No. US-----7119092 A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: O'Sullivan, Peter
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 3
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I):

##STR14# wherein


each R independently represents a halogen atom or a C.sub.1-4 alkyl group; R.sub.1 represents a C.sub.1-4 alkyl group; R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group; R.sub.3 represents hydrogen or C.sub.1-4 alkyl group; R.sub.4 represents a trifluoromethyl group; R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6; R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C1-4alkyl).sub.2; n is zero or an integer from 1 to 3; n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 414910-47-7P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenylethyl)-N-methylamide
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenylethyl)-N-methylamide 414910-48-8P,
 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-


L47 ANSWER 7 OF 9 USPAT2 on STN (Continued)
 RN 414910-46-6 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L47 ANSWER 8 OF 9 USPAT2 on STN
 AN 2005:15898 USPAT2
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Di Fabio, Romano, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 Tranquillini, Maria Elvira, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7060702 B2 20060613
 AI 2004US-000944605 20041122 (10)
 RLI Continuation of Ser. No. 2000US-000398264, PENDING A 371 of International Ser. No. 2001WO-GB0004580, filed on 12 Oct 2001
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: O'Sullivan, Peter
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 79
 ECL Exemplary Claim: 1
 DWMN No Drawings
 LN.CNT 2203
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides compounds of formula (I):

##STR14# wherein
 each R independently represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen or C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C.sub.1-4alkyl).sub.2;
 m is zero or an integer from 1 to 3;
 n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(S)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




L47 ANSWER 8 OF 9 USPAT2 on STN (Continued)
 IT 414910-46-6P, 4-(R)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-46-6 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-48-8 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L47 ANSWER 9 OF 9 USPAT2 on STN
 AN 2004:19466 USPAT2
 TI Chemical compounds
 IN Alvaro, Giuseppe, Verona, ITALY
 Maragni, Paolo, Verona, ITALY
 Tampieri, Marsia, Verona, ITALY
 PA SmithKline Beecham Corporation, Philadelphia, PA, UNITED STATES (U.S. corporation)
 PI US-----7119092 B2 20061010
 WO-200203266 7 20020425 <--
 AI 2001US-000398264 20011012 (10) <--
 2001WO-GB0004580 20011012 <--
 PRAI 2000GB-000025354 20001017 <--
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Raymond, Richard L.
 LREP Morgan, Lorie Ann
 CLMN Number of Claims: 41
 ECL Exemplary Claim: 1
 DWMN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 1749
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

##STR14# wherein
 R represents a halogen atom or a C.sub.1-4 alkyl group;
 R.sub.1 represents a C.sub.1-4 alkyl group;
 R.sub.2 represents hydrogen or a C.sub.1-4 alkyl group;
 R.sub.3 represents hydrogen, or a C.sub.1-4 alkyl group;
 R.sub.4 represents a trifluoromethyl group;
 R.sub.5 represents hydrogen, a C.sub.1-4 alkyl group or C(O)R.sub.6;
 R.sub.6 represents C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, NH(C.sub.1-4 alkyl) or N(C.sub.1-4alkyl).sub.2;
 m is zero or an integer from 1 to 3;
 n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated by tachykinins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 414910-47-7P, 4-(S)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-47-7 USPAT2
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(4-cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 414910-46-6P, 4-(R)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-[(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[(1R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid

L47 ANSWER 9 OF 9 USPAT2 on STN (Continued)
phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-46-6 USPAT2

CN 1-Piperidinecarboxamide, N-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-48-8 USPAT2

CN 1-Piperidinecarboxamide, N-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

=> d his

(FILE 'HOME' ENTERED AT 10:50:55 ON 29 APR 2008)

FILE 'HCAPLUS' ENTERED AT 10:51:08 ON 29 APR 2008

L1 1 US20060293308/PN

FILE 'REGISTRY' ENTERED AT 10:51:20 ON 29 APR 2008

FILE 'HCAPLUS' ENTERED AT 10:51:22 ON 29 APR 2008

L2 TRA L1 1- RN : 56 TERMS

FILE 'REGISTRY' ENTERED AT 10:51:23 ON 29 APR 2008

L3 56 SEA L2

L4 43 L3 AND NC2NC2/ES AND NC5/ES

L5 43 L4 AND 46.156.30/RID

FILE 'REGISTRY' ENTERED AT 10:52:15 ON 29 APR 2008

L6 STR

L7 0 L6

L8 161791 NC5/ES AND NC2NC2/ES

L9 50 L6 SAM SUB=L8

L10 STR L6

L11 21 L10 SAM SUB=L8

L12 2038 L10 FULL SUB=L8

SAV TEM J857F1/A L12

L13 1 NAPHTHALENE/CN

L14 1854 (46.150.18 OR 591.49.57)/RID AND L12

L15 35 L14 AND L3

L16 1819 L14 NOT L15

FILE 'HCAPLUS' ENTERED AT 11:00:00 ON 29 APR 2008

L17 17 L16

L18 2 L15

L19 5 L17 AND (PD<=20030729 OR AD<=20030729 OR PRD<=20030729)

L20 3 L17 AND PD<=20020729

L21 5 L19-20

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 11:04:13 ON 29 APR 2008

L22 303 E1-303

FILE 'HCAOLD' ENTERED AT 11:12:56 ON 29 APR 2008

L23 0 L16

L24 0 L15

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:13:11 ON 29 APR 2008

L25 0 L15

L26 11 L16

L27 10 L26 AND (PD<=20030729 OR AD<=20030729 OR PRD<=20030729)

L28 1 L26 AND PD<=20020729

L29 10 L27-28

L30 0 L26 AND XENON/CS,PA

E ABREO M/AU

L31 21 E4-5

E HARVEY D/AU

L32 5 E3

E HARVEY DAN/AU

L33 19 E3,E5-11

L34 17 E3,E5-9

E KONDRATENKO M/AU

L35 3 E6-7

E LI W/AU

E LI WEN/AU

L36 182 E3

E LI WENBAO/AU

L37 7 E3

E LI WEN B/AU

E KAMBOJ R/AU

L38 56 E4-5
E WINTHER M/AU
L39 20 E6-7
E GSCHWEND H/AU
L40 41 E3,E5-7
E CHAKKA N/AU
L41 8 E4-5
E LIU S/AU
L42 1 E3
E LIU SHI/AU
E LIU SHIFENG/AU
L43 14 E3
E SVIRIDOV S/AU
L44 22 E4-7
E SUN S/AU
E SUN SHAO/AU
E SUN SHAOYI/AU
L45 11 E3
L46 1 L29 AND L26 AND L31-45
L47 9 L29 NOT L46

=>